What are the treatment options for migraines?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 31, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Migraine Treatment

For acute migraine treatment, start with NSAIDs (ibuprofen 400-800 mg, naproxen 500-825 mg, or aspirin 1000 mg) for mild-to-moderate attacks, and escalate immediately to a triptan plus NSAID combination for moderate-to-severe attacks or when NSAIDs fail. 1

Acute Treatment Algorithm

Mild-to-Moderate Attacks (First-Line)

  • NSAIDs are the initial choice: ibuprofen 400-800 mg, naproxen sodium 500-825 mg, aspirin 1000 mg, or diclofenac potassium 2, 1
  • Alternative first-line option: aspirin-acetaminophen-caffeine combination (number needed to treat = 4 for pain relief at 2 hours) 1
  • Acetaminophen 1000 mg can be used but has inferior efficacy compared to NSAIDs 1, 3
  • Critical timing: Take medication as early as possible when headache is still mild to maximize effectiveness 1, 4

Moderate-to-Severe Attacks (Second-Line)

  • Triptans are first-line for moderate-to-severe attacks: sumatriptan 50-100 mg, rizatriptan, naratriptan, or zolmitriptan 2, 1
  • Combination therapy is superior: triptan plus NSAID (e.g., sumatriptan 50-100 mg + naproxen 500 mg) provides 130 more patients per 1000 achieving sustained pain relief at 48 hours compared to either agent alone 1, 5
  • Subcutaneous sumatriptan 6 mg provides highest efficacy (59% pain-free at 2 hours) with onset within 15 minutes for rapid progression or severe vomiting 5, 4
  • If one triptan fails, try a different triptan as failure of one does not predict failure of others 1, 5

Refractory Attacks (Third-Line)

  • For patients failing all triptans or with triptan contraindications: CGRP antagonists (rimegepant, ubrogepant, zavegepant), lasmiditan, or dihydroergotamine 1, 3
  • Rimegepant and ubrogepant have number needed to treat = 13 for pain freedom at 2 hours 1
  • Lasmiditan has robust efficacy but significant adverse effects including driving restrictions (number needed to harm = 4) 1

Managing Associated Symptoms

Nausea and Vomiting

  • Metoclopramide 10 mg IV/PO provides dual benefit: treats nausea and provides direct analgesic effects through central dopamine receptor antagonism 1, 5
  • Prochlorperazine 10 mg IV/PO is equally effective as metoclopramide with comparable efficacy 1, 5
  • Use non-oral routes (intranasal, subcutaneous, IV) when significant nausea or vomiting is present 1, 5

Emergency/Urgent Care Treatment

IV Combination Therapy

  • First-line IV cocktail: metoclopramide 10 mg IV plus ketorolac 30 mg IV provides rapid relief with minimal rebound risk 1, 5
  • Ketorolac has rapid onset with approximately 6 hours duration 1, 5
  • Alternative IV option: dihydroergotamine (DHE) has good evidence as monotherapy 1, 5

Critical Medication Frequency Limits

Limit all acute medications to ≤2 days per week to prevent medication-overuse headache (MOH). 1, 5, 3

  • NSAIDs: maximum 15 days per month 1, 3
  • Triptans: maximum 10 days per month 1, 3
  • Exceeding these limits leads to MOH, causing daily headaches and treatment resistance 2, 1
  • If needing acute treatment >2 days/week, initiate preventive therapy immediately 1, 5

Preventive Therapy Indications

Consider preventive treatment when: 1

  • ≥2 attacks per month producing disability lasting ≥3 days
  • Contraindication to or failure of acute treatments
  • Using acute medication >2 days per week
  • Presence of uncommon migraine conditions (hemiplegic migraine, prolonged aura)

First-Line Preventive Options

  • Beta-blockers: propranolol 80-240 mg/day or timolol 20-30 mg/day 1, 5
  • Topiramate: effective but requires discussion of teratogenic effects with patients of childbearing potential 1
  • OnabotulinumtoxinA 155 units: FDA-approved specifically for chronic migraine (≥15 headache days/month) 1
  • CGRP monoclonal antibodies: for patients failing oral preventives, assess efficacy after 3-6 months 1, 5

Medications to Avoid

Never use opioids or butalbital-containing analgesics for routine migraine treatment as they lead to dependency, rebound headaches, and loss of efficacy. 1, 5, 3

Special Populations

Pregnancy and Breastfeeding

  • Acetaminophen is first-line for acute treatment 2, 1
  • NSAIDs can be used prior to third trimester 3
  • Avoid preventive treatment if possible 2
  • Sodium valproate is absolutely contraindicated due to teratogenic risk 2, 1

Children and Adolescents

  • Bed rest alone can be sufficient 2
  • Ibuprofen for acute treatment 2
  • Propranolol, amitriptyline, or topiramate for prevention 2

Older Adults

  • Secondary headache, comorbidities, and adverse events are more likely 2
  • Poor evidence base for all drugs in this age group 2

Lifestyle Modifications

Essential non-pharmacologic interventions: 1, 3

  • Regular moderate-to-intense aerobic exercise (40 minutes, 3 times weekly) - as effective as some preventive medications 1
  • Maintain regular meals and adequate hydration 1
  • Ensure consistent, sufficient sleep 1
  • Stress management with relaxation techniques or mindfulness 1
  • Identify and reduce triggers using a headache diary 1, 5

Contraindications to Triptans

Triptans are contraindicated in: 4

  • Ischemic heart disease or previous myocardial infarction
  • Prinzmetal's variant angina
  • Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders
  • History of stroke or transient ischemic attack
  • Uncontrolled hypertension
  • Hemiplegic or basilar migraine

Common Pitfalls to Avoid

  • Taking medication too late in the attack - efficacy decreases significantly if not taken when pain is still mild 1, 4
  • Using monotherapy when combination therapy is indicated - triptan plus NSAID is superior to either alone for moderate-to-severe attacks 1, 5
  • Allowing patients to increase acute medication frequency rather than transitioning to preventive therapy 5
  • Not recognizing medication-overuse headache - presents as daily headaches or marked increase in migraine frequency 2, 4

References

Guideline

Migraine Treatment Strategies

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Migraine Headache Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Acute Headache Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.